1800 202 8726
Breast cancer recurrence

Should ER, PR and HER2 Markers — Be Retested When Cancer Returns?

Your breast cancer markers can change between your first diagnosis and a recurrence. A tumour that was ER positive may return ER negative, or vice versa. Treating a recurrence on old results means treating a tumour that may no longer exist.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026

  • Markers can switch — ER, PR and HER2 status can convert at recurrence — positive can become negative and negative can become positive.
  • Guidelines say retest — ESMO and ASCO both recommend retesting receptor status on a new biopsy before any treatment decision is made.
  • Treatment follows the new biology — The recurrence, not the original tumour, determines what treatment is now appropriate.
  • One test can change the plan — A changed marker can redirect the entire treatment pathway — which is why the test is worth doing.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Talk to a medical oncologist

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

Yes. ER, PR and HER2 status can change between your first tumour and a recurrence. ESMO and ASCO both recommend retesting marker status on a new biopsy when breast cancer returns, because treatment is decided on the biology of the tumour you have now — not the tumour from years ago.

What is the risk of treating on the original markers?

Using original markers onlyRetesting at recurrence
ER and PR statusAssumed unchanged from diagnosisConfirmed — can convert in either direction
HER2 statusAssumed unchanged from diagnosisConfirmed — can become positive or negative
Basis for treatmentBiology from the original tumourBiology of the actual recurrence
Alignment with guidelinesNot in line with current ESMO or ASCO guidanceAligned — both bodies recommend rebiopsy when feasible
Main riskTreatment may not match the current tumourRisk of mismatch is eliminated

Do markers always stay the same as at your first diagnosis?

No. Tumours can change over time, and the biology of a recurrence is not always the same as the original. ER status, PR status and HER2 status have all been shown to convert — sometimes from positive to negative, sometimes the other way.

This is not a sign that the first test was wrong. It reflects the fact that tumours can evolve, and the cells driving the recurrence may have a different profile from the cells present at diagnosis.

ESMO guidelines specifically note this as the reason retesting is recommended. The treatment approach follows the biology of the recurrence — and you cannot know that biology without testing the new tissue.

Not sure what this means for you?

Share your reports and a senior oncologist will explain your options in plain language — no obligation to start treatment.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

You do not have to work this out alone

A 45-minute consultation with a specialist who treats this every week.

Book Free Consultation Call 1800 202 8726

What do ER, PR, HER2 and Ki-67 actually mean?

ER positive
Oestrogen receptor positive. The cancer cells carry receptors that respond to oestrogen, which can drive their growth. This is the most common breast cancer subtype.
ER negative
The cancer cells do not carry oestrogen receptors. A tumour that was ER positive at first diagnosis can return ER negative, and vice versa — which is why the recurrence needs its own test.
PR positive / negative
Progesterone receptor status. PR and ER are tested together and reported alongside each other. PR status can also change at recurrence, independently of what ER does.
HER2 positive
The cancer cells have extra copies of the HER2 gene or excess HER2 protein on their surface. HER2 conversion between original tumour and recurrence is documented and clinically significant.
Ki-67
A marker of how quickly cancer cells are dividing. Ki-67 can change at recurrence and gives your team a picture of how fast the recurrence is growing.
Receptor conversion
When a marker status changes between the original tumour and the recurrence. ESMO and ASCO treat this as a known possibility and the primary reason retesting is recommended before treatment is started.

What should you ask your oncologist when a recurrence is confirmed?

  • Ask whether a biopsy of the recurrent or metastatic site is being planned.
  • Ask for ER, PR and HER2 to be tested on the new sample — and Ki-67 if not already included.
  • Keep a copy of both your original pathology report and any new one.
  • Tell your team if the biopsy was done at another centre, so the results or tissue blocks can be shared.
  • Ask how the new marker results compare to your original profile.
  • Ask your oncologist what any change in marker status means for your treatment options now.

Did you know?

In a meaningful proportion of breast cancer recurrences, at least one receptor marker differs from the original tumour — enough that ESMO guidelines class retesting as a standard step before any treatment decision is made.

A conversion in HER2 status, even when less common than ER or PR conversion, can redirect an entire treatment plan.

Source: ESMO Clinical Practice Guidelines: Metastatic Breast Cancer

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

HUB — How Accurate Is a Biopsy? Repeats, Errors and Second Opinions

HUB — IHC and Molecular Markers on a Biopsy

HUB — Labs, Slides and Second Opinions on a Biopsy

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

If my ER positive tumour returns as ER negative, does that mean my treatment has failed?

Not necessarily. Receptor conversion at recurrence does not mean your earlier treatment failed — it means the tumour's biology has shifted, which is a recognised pattern. What it does mean is that your current treatment plan will be based on the new marker profile, not the old one. Your oncologist will explain what the conversion means specifically for your situation and what the options now look like.

Does retesting always require a new biopsy?

Yes. Imaging — CT, PET-CT or bone scan — can locate a recurrence but cannot tell you its receptor status. A tissue sample from the recurrent site is needed to confirm the markers. In some situations, such as a bone metastasis, the biopsy requires more planning, but it is still usually attempted because the result directly shapes the treatment. Ask your oncologist whether the planned biopsy will include full marker testing.

My doctor says my HER2 status has changed. Is that actually possible?

Yes. HER2 conversion between a primary tumour and a recurrence is well-documented. It can go in either direction — from HER2 positive to negative, or from negative to positive. It is less common than ER or PR conversion, but it is one of the reasons guidelines recommend retesting. HER2 status influences which treatment pathways are available, so a confirmed change is clinically important and worth discussing in detail with your oncologist.

Should Ki-67 also be retested at recurrence?

Yes, and it is worth asking for specifically. Ki-67 reflects how fast the cancer cells are dividing, and this can change between the original tumour and a recurrence. A higher Ki-67 at recurrence may indicate a more rapidly growing tumour. Ask your team to include Ki-67 in the pathology request for the new biopsy, especially if it was low at your original diagnosis — the change in proliferation rate is part of what your oncologist uses to make treatment decisions.

What if the recurrence is in a place that is hard to biopsy?

Your team will weigh the value of the marker information against the difficulty and risk of the biopsy. For liver metastases, lung nodules and lymph nodes, biopsy is relatively straightforward. For bone metastases it requires more planning but is still often feasible. Where biopsy carries too much risk, your oncologist may use the original marker profile as a guide while acknowledging its limitations. Liquid biopsy — testing circulating tumour DNA in a blood sample — is an active area of research but is not yet standard practice for confirming receptor status.

How long will the new marker results take?

Once the laboratory receives the biopsy sample, marker testing typically takes one to two weeks, though the total time also includes the days needed for tissue processing after the biopsy procedure. Ask your team when the sample was sent and when the result is expected, so you have a realistic timeline. If the biopsy was done at another centre, ask how the results will reach your treating oncologist.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation